Clinical trial · Observational
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Head and Neck Cancer
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites During the Occurrence and Development of Head and Neck Cancer in Southern China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Dynamic changes in the internal environment of the body are important clues for early detection, diagnosis and even cure of head and neck tumors. This project uses the combination of proteomics technology and liquid biopsy to provide more primary prevention strategies for early intervention, secondary prevention strategies for early detection and treatment, and clues for the study of the mechanism of dynamic evolution of head and neck tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Metabolite | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proteomics technology and liquid biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Head and neck cancer patients
- description
- Patients who meet the diagnostic criteria of the Guidelines for Diagnosis and Treatment of Head and Neck Cancer
- interventionNames
- Diagnostic Test: Proteomics technology and liquid biopsy
- label
- Healthy people
- description
- Healthy people without liver related medical history or other diseases known to affect blood lipid/protein metabolism.
- interventionNames
- Diagnostic Test: Proteomics technology and liquid biopsy
Primary outcomes (1)
- measure
- Achieve the expected number of enrolled cases
- timeFrame
- 3 years
- description
- 1. Retrospective cohort: 250 patients were recruited, including 125 patients with head and neck cancer, 125 healthy people. 2. Prospective cohort: 250 patients were recruited, including 125 head and neck cancer patients and 125 healthy people.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Head and neck cancer patients * Age 18-75 years old; * Male or non-pregnant female; * Patients who were normatively diagnosed as head and neck tumors according to the WHO standards of 2017; * The general situation is good: KPS score ≥70; * No other malignant tumors. 2. Healthy people * Age 18-75 years old; * Male or non-pregnant female; * No history of head and neck related diseases or other diseases known to affect blood lipid/protein metabolism. Exclusion Criteria: * Previous history of non-research related head and neck conditions or other known effects on blood metabolism (except for controlled type 2 diabetes); * With a history of other malignancies (except cell carcinoma and cervical carcinoma in situ); * Diseases that require long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency disorders or active central nervous system rotations, metastatic cancer, active infection, or uncontrolled heart disease; * Concurrent with other uncontrolled serious medical conditions, such as unstable heart disease that requires treatment Disease, poorly controlled diabetes (fasting blood glucose \> 1.5× the upper limit of normal), mental illness and a history of severe allergies. * BMI less than 18 or greater than 25.
References
Publications (0)
Data not yet available